Home
Journal Information
About
Aims and Scope
Contacts and Editorial Office
Editorial Board
Editor in Chief
Publisher
Conflicts of Interest
Editorial Policies
Publication Ethics
Nickan Research Institute policy
DISCLAIMER
Open Access
Journal Issues
Current Issue
In Press
Archive
Guidelines
For Authors
For Authors-New
For Reviewers
Peer Review Process in JRIP
Peer Review Process flowchart in JRIP
Authors agreement form
Checklist for review
Editorial Workflow
Publication Ethics and Malpractice Statement
Human and animal right
Informed Consent
Create Account
Login
Please don't use dangerous characters
Title
Author
Abstract
Keywords
First Name
Last Name
Search
eISSN
:
2345-2781
Submit Your Paper
Editorial Board
Aims and Scope
Publisher
Publication Fee
Contact Us
Archive
Indexing Information
Member of
Follower of
J Renal Inj Prev
. 2017;6(2): 88-92. doi:
10.15171/jrip.2017.17
PMID:
28497081
PMCID:
PMC5423290
Original Article
Relationship between serum irisin, glycemic indices, and renal function in type 2 diabetic patients
Leila Mahmoodnia
1
, Maryam Sadoughi
1
, Ali Ahmadi
2
, Marzieh Kafeshani
3
*
Cited by CrossRef: 10
1- Salama D, Hammad F, Mohamed E, Ahmad I. Serum irisin level and its relation to diabetic nephropathy in patients with type 2 diabetes mellitus. 2021;5(2):347
[Crossref]
2- Mazloum Khorasani Z, Hosseini S, Safaei M, Mehrad Majd H, Sarabi M, Torshizian A, Nikpasand N, Saeedi N, AkbariRad M. The role of serum level of irisin in diabetic retinopathy.
Int J Diabetes Dev Ctries
. 2024;44(2):350
[Crossref]
3- Gao Q, Lu C, Wang X, Zhang J, Song Y, Xue Y. Molecular dynamics simulation and steered molecular dynamics simulation on irisin dimers.
J Mol Model
. 2018;24(4)
[Crossref]
4- Ali E, Ali A, Al Ramly A, Muhamed M. Evaluation of serum irisin level in patients with chronic kidney disease. 2021;5(1):47
[Crossref]
5- El Haddad H, Sedrak H, Naguib M, Yousief E, Ibrahim D, Abdel Samie R, Hamdy A. Irisin level in type 2 diabetic patients and its relation to glycemic control and diabetic complications.
Int J Diabetes Dev Ctries
. 2019;39(4):641
[Crossref]
6- Al-Rubaye A, Jasim W, Mohsin A. Myonectin, irisin, apelin-13 and Elabela hormones levels as biomarkers for type 2 diabetes mellitus : a systematic review.
UkrBiochemJ
. 2024;96(4):17
[Crossref]
7- He C, He W, Hou J, Chen K, Huang M, Yang M, Luo X, Li C. Bone and Muscle Crosstalk in Aging.
Front Cell Dev Biol
. 2020;8
[Crossref]
8- Deng X, Huang W, Peng J, Zhu T, Sun X, Zhou X, Yang H, Xiong J, He H, Xu Y, He Y. Irisin Alleviates Advanced Glycation End Products-Induced Inflammation and Endothelial Dysfunction via Inhibiting ROS-NLRP3 Inflammasome Signaling.
Inflammation
. 2018;41(1):260
[Crossref]
9- Nayak S, Sahu P, Sahu R, Mahapatra S, Mohapatra D. Irisin levels in type 2 diabetes mellitus with and without non-alcoholic fatty liver disease: a case-control study.
Prosp Pharm Sc
. 2024;22(3):210
[Crossref]
10- Aghasi M, Ghazi-Zahedi S, Koohdani F, Siassi F, Nasli-Esfahani E, Keshavarz A, Qorbani M, Khoshamal H, Salari-Moghaddam A, Sotoudeh G. The effects of green cardamom supplementation on blood glucose, lipids profile, oxidative stress, sirtuin-1 and irisin in type 2 diabetic patients: a study protocol for a randomized placebo-controlled clinical trial.
BMC Complement Altern Med
. 2018;18(1)
[Crossref]
11- Ma J, Chen K. The role of Irisin in multiorgan protection.
Mol Biol Rep
. 2021;48(1):763
[Crossref]
12- Riwayadi D, Ambardini R, Sutapa P, Hardianto D, Ali S, Karakauki M, Aryanto S, Pratama K, Utami D, Kristianto A. Moderate Intensity Interval Training (MIIT) and High Intensity Interval Training (HIIT) exercise therapy against irisin levels in obesity.
Fiz Pol
. 2024;24(4):136
[Crossref]
13- Colaianni G, Errede M, Sanesi L, Notarnicola A, Celi M, Zerlotin R, Storlino G, Pignataro P, Oranger A, Pesce V, Tarantino U, Moretti B, Grano M. In Reply to the Letter to the Editor: Involvement of Irisin in Age-Related Osteoporosis and Its Inhibitory Effect on the Senescent Marker p21 in Osteoblasts. 2020;36(7):1420
[Crossref]